iators. Consider appropriate follow up regarding your microbiome analysis. Off label pharmacological management for elevated triglycerides include Lomitapide, which interferes with apoB-containing lipoprotein assembly in the apoBloo and apoB48 pathways, thus reducing both chylomicron and VLDL secretion.